SECTOR SYSTEM / 12 COVERED ISSUERS
Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.
Product concentration, research investment, utilization, reimbursement and cash generation.
Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.
Sector medians are descriptive, not fair-value estimates. Dated company ratios use annual denominators and differ in fiscal year end. Historical-multiple series are unavailable. Sources and exclusions are visible on company profiles.
Across 8 eligible healthcare companies, the equal-weight median capital expenditure as a share of revenue was 3.93% for the prior selected annual periods.
Across 8 eligible healthcare companies, the equal-weight median capital expenditure as a share of revenue was 4.55% for the latest selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median operating cash-flow margin was 27.32% for the prior selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median operating cash-flow margin was 26.04% for the latest selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median equity as a share of assets was 39.55% for the prior selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median equity as a share of assets was 41.54% for the latest selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median net margin was 13.02% for the prior selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median net margin was 28.08% for the latest selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median revenue growth was 11.66% for the prior selected annual periods.
Across 11 eligible healthcare companies, the equal-weight median revenue growth was 8.57% for the latest selected annual periods.
AbbVie Inc.
A two-period review of ABBV revenue, profitability and cash conversion; reported revenue growth was 8.57%.
AbbVie Inc.
Annual revenue of USD 61.160 billion and net income of USD 4.226 billion for the period ended 2025-12-31.
ABBOTT LABORATORIES
Annual revenue of USD 44.328 billion and net income of USD 6.524 billion for the period ended 2025-12-31.
AMGEN INC
Annual revenue of USD 36.751 billion and net income of USD 7.711 billion for the period ended 2025-12-31.
ASTRAZENECA PLC
Annual revenue of USD 58.739 billion and net income of USD 10.233 billion for the period ended 2025-12-31.
GILEAD SCIENCES, INC.
Annual revenue of USD 29.443 billion and net income of USD 8.510 billion for the period ended 2025-12-31.